ArticleCA: a cancer journal for clinicians2018

Immune checkpoint inhibitors are superior to docetaxel as second-line therapy for patients with non-small cell lung carcinoma.

Mike FillonPubMed ↗Publisher ↗

No numbers read from the abstract.